


## ZLWT-37

Cat. No.:	HY-147771
CAS No.:	2813347-44-1
Molecular Formula:	C <sub>26</sub> H <sub>30</sub> ClN <sub>5</sub> O
Molecular Weight:	464
Target:	CDK; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

<b>Description</b>	ZLWT-37 is a potent, orally active CDKs inhibitor with IC <sub>50</sub> values of 0.002 μM and 0.054 μM against CDK9 and CDK2, respectively. ZLWT-37 induces apoptosis and arrests the cell cycle in the G2/M phase in HCT116 cells <sup>[1]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	CDK9 0.002 μM (IC <sub>50</sub> )	CDK2 0.054 μM (IC <sub>50</sub> )
<b>In Vitro</b>	ZLWT-37 shows antiproliferative activity with a GI <sub>50</sub> of 0.029 μM for HCT116 <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	ZLWT-37 (0-20 mg/kg; p.o.; once daily for 14 consecutive days) shows potential efficacy against the growth of implanted HCT116 cells in mice without obvious toxicity <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

## REFERENCES

[1]. Liu W, et al. Discovery of novel tacrine derivatives as potent antiproliferative agents with CDKs inhibitory property. *Bioorg Chem.* 2022 Sep;126:105875.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA